| Autor: |
Roschewski, M., Simard, J., Melani, C., Lakhotia, R., Phelan, J. D., Pittaluga, S., Muppidi, J. R., Lionakis, M. S., Peer, C., Pradhan, A., Holdhoff, M., Swinnen, L. J., Dunleavy, K., Lai, C., Ibrahimi, S., Glantz, M., Butman, J. A., Johnson, K., Steinberg, S. M., Figg, W. D. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p44-46, 3p |
| Abstrakt: |
Pts with >=20% reduction after ibrutinib received TEDDi-R; those with <20% reduction received TEDD-R. Therapy was 4 cycles × 21d with IT therapy (no maintenance) and mostly outpatient. The 1-year PFS and OS for pts with CD10 neg tumors was 48.0% and 64.7% B Conclusions: b Ibrutinib-responsive SCNSL achieves high rates of CR to TEDDi-R that can be durable. Ibrutinib-responsive tumors are mostly CD10 negative and TEDDi-R may improve the outcomes of this subgroup. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text